BOT

BOTANIX FPO [BOT]
Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0210 +0.0%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when BOT triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track BOT — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Watch out — volume is flowing out even as price holds up. Distribution pattern
  • Low cash runway (2 quarters) - dilution risk
  • Low P/S ratio (1.7x)
  • Strong revenue growth (+220%)
  • Near 52-week low (2% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (10%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 82% over the past year
  • Poor risk-adjusted returns — Sharpe of -2.1 means lots of volatility for not much reward
  • Revenue growing at +220% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.44%/day)
  • Low-priced stock risk ($0.021)
  • Beneish M-Score 1.20 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-206%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about BOT
"What's driving BOT today?" "How does BOT compare to peers?" "Key risks for BOT?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Change of Director's Interest Notice
NONE Notification of cessation of securities - BOT
NONE Appendix 4G and Corporate Governance Statement
LOW Appendix 4E & Annual Report for the Year Ended 30 June 2026

Recent ASX Announcements

2026-08-31 Change of Director's Interest Notice
2026-08-31 Notification of cessation of securities - BOT
2026-08-26 Appendix 4G and Corporate Governance Statement
2026-08-26 Appendix 4E & Annual Report for the Year Ended 30 June 2026 PRICE SENSITIVE
2026-08-14 Notification regarding unquoted securities - BOT

Key Metrics

$57.5M
Market Cap
5.5M
Avg Volume
1.0x
Vol Ratio
$0.02 — $0.17
52-Week Range
0.7%
Short Interest
N/A
Cash Runway
-96.4%
ROE
-206.4%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 96%
LLeader vs LaggardlaggardRS: -4
IInstitutional SponsorshippassInst: 10%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:BOT vs REGBOT vs CANBOT vs BIT
Scout Pro — Deeper Analysis for BOT
Try Pro free for 30 days
Share this analysis

Track BOT and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required